Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neurofibroma, Plexiform × Control Groups × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasms 1 Keratosis, Actinic 1 Heart Failure 1 Gastrointestinal Neoplasms 1 Disease 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Arrhythmias, Cardiac 1

Interventions

AZD 6244 4 mirdametinib 2 trametinib 1 dabrafenib 1 Everolimus 1 Control Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡